arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Gain Therapeutics, Inc.

GANX

$1.85 ▼ -0.10 (-5.13%) at close

7 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

Gain Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $61.0M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -103.1% ↗

FCF / Share $-0.56 ↗

Trailing P/E —

Price / Book 4.2x

FCF Yield —

Debt / Equity 0.02

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$55.18K

↓ -60.6% —

Net Income Profit after all expenses

$-20.16M

↑ +1.2% —

FCF / Share Free cash flow per share

$-0.56

↑ +32.1% —

Long-Term Debt Long-term obligations

$400.95K

↓ -8.6% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	-60.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-858%)	-15.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-289%)	471.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5791%)	—	—
EPS Growth YoY (%)	31.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	48.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-15.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-8.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-3.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	1.2% Caution ↑ Caution Improving Year-over-year change in net income	8.3% Fair ↑ Fair Improving Year-over-year change in net income	-26.6% Weak ↑ Weak Improving Year-over-year change in net income	-26.6% Weak Weak Year-over-year change in net income	-288.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	32.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	43.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-17.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	-0.9% Weak Weak Year-over-year change in free cash flow	-0.8% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	—	24.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-4.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-103.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-268.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-169.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-91.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-50.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-82.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-167.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-119.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-36.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-108.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-824%)	-278.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1954%)	-177.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1280%)	-93.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-721%)	-39.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-366%)	-57.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-485%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.02x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-96%)	0.06x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-90%)	0.05x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-92%)	0.03x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-95%)	0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-97%)	0.12x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-81%)	—
Net Debt (USD)	$-20.44M	$-9.95M	$-11.23M	$-6.71M	$-36.19M	$-6.78M	—
Debt / EBITDA (x)	-0.02x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.02x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.03x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.03x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.05x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.21x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	$0.00	$0.01	$0.02	$0.01	—
Basic EPS, GAAP (USD)	$-0.61	$-0.89	$-1.71	$-1.48	$-1.37	$-1.33	—
Free Cash Flow per Share (USD)	$-0.56	$-0.82	$-1.45	$-1.24	$-1.23	$-1.22	—
Book Value per Share (USD)	$0.44	$0.27	$0.78	$1.59	$2.93	$1.75	—
Tangible Book Value per Share (USD)	$0.44	$0.27	$0.78	$1.59	$2.93	$1.75	—
Basic Weighted Avg Shares (shares)	32.97M	22.88M	13.01M	11.88M	10.17M	2.68M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$18.88M	$7.69M	$12.83M	$16.97M	$35.17M	$6.87M	—
LT Debt (USD)	$400.95K	$438.50K	$567.85K	$603.39K	$694.29K	$715.66K	—
Total Equity (USD)	$18.56M	$7.34M	$12.58M	$18.88M	$34.82M	$6.20M	$-449.86K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$55.18K	$140.11K	$164.99K	$28.88K	—
Depreciation Expense (USD)	$94.05K	$84.07K	$83.58K	$64.17K	$15.48K	$9.59K	—
Net Income, GAAP (USD)	$-20.16M	$-20.41M	$-22.27M	$-17.59M	$-13.89M	$-3.58M	—
Operating Cash Flow (USD)	$-18.47M	$-18.87M	$-18.87M	$-14.69M	$-12.37M	$-3.24M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Gain Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare GANX with peers